Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OMID HAMID

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215966775
CMS profile
55583
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$108,808.92

72 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OMID HAMID

NPI 1215966775 · CMS profile ID 55583

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215966775?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OMID HAMID, NPI 1215966775, CMS profile ID 55583. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215966775?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). OMID HAMID, NPI 1215966775, CMS profile ID 55583. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215966775?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
OMID HAMID, NPI 1215966775, CMS profile ID 55583, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–72 of 72 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1215966775?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

72 matching records · $108,808.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 72 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–72 of 72.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Immunocore Limited $437.5004/30/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103098685 CMS
Immunocore Limited $1,050.0004/23/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103098659 CMS
Merck Sharp & Dohme LLC $383.0704/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141907382 CMS
Merck Sharp & Dohme LLC $48.6904/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811985 CMS
Merck Sharp & Dohme LLC $32.4604/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141907240 CMS
Merck Sharp & Dohme LLC $383.0704/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811961 CMS
Merck Sharp & Dohme LLC $238.0604/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811963 CMS
Merck Sharp & Dohme LLC $238.0604/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811965 CMS
Merck Sharp & Dohme LLC $10,367.3004/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141811983 CMS
Immunocore Limited $3,062.5004/09/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103098649 CMS
Bayer Healthcare Pharmaceuticals Inc. $5,240.2503/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086223420 CMS
Regeneron Healthcare Solutions, Inc. $5,286.0003/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114063906 CMS
Regeneron Healthcare Solutions, Inc. $114.4102/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114063904 CMS
Immunocore Limited $700.0002/26/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103098625 CMS
ARRAY BIOPHARMA INC $4.1702/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131565783 CMS
EMD Serono, Inc. $21.1302/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120225671 CMS
Immunocore Limited $700.0002/13/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103098619 CMS
Regeneron Pharmaceuticals, Inc. $3,745.0001/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114399819 CMS
EMD Serono, Inc. $18.0001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120225837 CMS
E.R. Squibb & Sons, L.L.C. $6,988.0001/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101503098 CMS
E.R. Squibb & Sons, L.L.C. $775.2101/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101503090 CMS
E.R. Squibb & Sons, L.L.C. $104.6001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101503094 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $156,523.68 127
PY2020 $82,715.52 36
PY2021 $98,731.45 49
PY2022 $151,012.98 90
PY2023 $103,501.13 75
PY2024 $108,808.92 72
PY2025 $108,183.08 63

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,552.78 10
PY2025 Principal investigator $2,050,900.19 353
PY2024 Recipient $3,313.87 12
PY2024 Principal investigator $1,029,726.05 139
PY2023 Recipient $12,340.57 43
PY2023 Principal investigator $3,058,770.58 554
PY2022 Recipient $6,573.85 21
PY2022 Principal investigator $3,959,470.39 564
PY2021 Recipient $2,051.30 3
PY2021 Principal investigator $3,633,687.21 452
PY2020 Recipient $4,140.00 2
PY2020 Principal investigator $3,869,603.69 702
PY2019 Recipient $19,310.95 3
PY2019 Principal investigator $5,330,060.34 887

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

363 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Pharma SAS $780.36 12/31/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303477
Principal investigator 1 Ipsen Pharma SAS $1,170.54 12/31/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303479
Principal investigator 1 Merck Sharp & Dohme LLC $5,762.51 12/31/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02D No dispute reported 06/30/2026 1232924598
Principal investigator 1 Merck Sharp & Dohme LLC $17,426.75 12/31/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02B No dispute reported 06/30/2026 1232924810
Principal investigator 1 Merck Sharp & Dohme LLC $5,394.04 12/31/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02A No dispute reported 06/30/2026 1232924854
Principal investigator 1 Merck Sharp & Dohme LLC $6,285.48 12/31/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02C No dispute reported 06/30/2026 1232925229
Principal investigator 1 Merck Sharp & Dohme LLC $18,435.62 12/31/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926129
Principal investigator 1 PFIZER INC. $12,183.06 12/31/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228816266
Principal investigator 1 Iovance Biotherapeutics, Inc. $624.00 12/24/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252499213
Principal investigator 1 Ipsen Pharma SAS $3,057.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303865
Principal investigator 1 Ipsen Pharma SAS $2,361.68 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303867
Principal investigator 1 Ipsen Pharma SAS $2,082.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303869
Principal investigator 1 Ipsen Pharma SAS $3,057.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303871
Principal investigator 1 Ipsen Pharma SAS $3,792.57 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303873
Principal investigator 1 Ipsen Pharma SAS $2,890.78 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303875
Principal investigator 1 Ipsen Pharma SAS $2,890.78 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303877
Principal investigator 1 Ipsen Pharma SAS $2,082.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303879
Principal investigator 1 Ipsen Pharma SAS $1,887.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303881
Principal investigator 1 Ipsen Pharma SAS $3,057.18 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303883
Principal investigator 1 Ipsen Pharma SAS $2,361.68 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303885
Principal investigator 1 Ipsen Pharma SAS $3,792.57 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303887
Principal investigator 1 Ipsen Pharma SAS $2,767.28 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303889
Principal investigator 1 Ipsen Pharma SAS $2,890.78 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303891
Principal investigator 1 Ipsen Pharma SAS $2,890.78 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303893
Principal investigator 1 Ipsen Pharma SAS $3,792.57 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303895
Principal investigator 1 Ipsen Pharma SAS $5,620.37 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303897
Principal investigator 1 Ipsen Pharma SAS $3,792.57 12/24/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303899
Principal investigator 1 Ipsen Pharma SAS $724.00 12/23/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303471
Principal investigator 1 Ipsen Pharma SAS $7,539.00 12/23/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303473
Principal investigator 1 Ipsen Pharma SAS $195.09 12/19/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303467
Principal investigator 1 Ipsen Pharma SAS $15,078.00 12/19/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303469
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $54.00 12/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051667
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,116.71 12/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051669
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $114.75 12/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051671
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $472.50 12/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051673
Principal investigator 1 Ipsen Pharma SAS $1,364.52 12/12/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303463
Principal investigator 1 Ipsen Pharma SAS $6,226.15 12/12/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303465
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,250.00 12/11/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498411
Principal investigator 1 Iovance Biotherapeutics, Inc. $375.00 12/11/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498413
Principal investigator 1 PFIZER INC. $23,310.25 12/11/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228815412
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,641.06 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,640.00 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,500.00 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,456.00 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37,821.00 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,386.00 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613 No dispute reported 06/30/2026 1184274590
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,300.82 12/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051665
Principal investigator 1 Ipsen Pharma SAS $68.00 12/08/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $594.18 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269759
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.07 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $292.05 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $409.32 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269767
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269769
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $238.23 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $409.68 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269773
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.52 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269775
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.07 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269777
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $145.98 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269779
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $72.54 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.57 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.57 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.57 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269791
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.25 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269793
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,814.67 12/08/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184269795
Principal investigator 1 Ipsen Pharma SAS $10,233.89 12/04/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303457
Principal investigator 1 Ipsen Pharma SAS $6,234.41 12/04/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303459
Principal investigator 1 Ipsen Pharma SAS $1,170.54 12/04/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303461
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,967.00 12/02/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252499215
Principal investigator 1 Iovance Biotherapeutics, Inc. $650.00 12/02/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252499217
Principal investigator 1 Merck Sharp & Dohme LLC $63,513.05 12/01/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926127
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $35,130.00 11/26/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants with Advanced Solid Tumors No dispute reported 06/30/2026 1236001645
Principal investigator 1 PFIZER INC. $7,458.05 11/26/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228818432
Principal investigator 1 PFIZER INC. $15,650.87 11/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228713674
Principal investigator 1 Ipsen Pharma SAS $682.26 11/18/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303451
Principal investigator 1 Ipsen Pharma SAS $1,253.49 11/18/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303453
Principal investigator 1 Ipsen Pharma SAS $1,365.63 11/18/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303455
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,077.74 11/13/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498409
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $521.10 11/07/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,550.00 11/05/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257451
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,092.00 11/05/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 11/05/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,950.00 11/05/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257457
Principal investigator 1 PFIZER INC. $20,108.25 11/04/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228818427
Principal investigator 1 Ipsen Pharma SAS $147.00 10/31/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $585.00 10/29/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184253939
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,304.88 10/09/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051661
Principal investigator 1 Iovance Biotherapeutics, Inc. $596.00 10/06/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252499211
Principal investigator 1 Merck Sharp & Dohme LLC $58,662.92 10/06/2025 Non-covered Recipient Entity
The Angeles Clinic and Research Institute
A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma KEYMAKER-U02# Substudy 02A No dispute reported 06/30/2026 1232924806
Recipient F. Hoffmann-La Roche AG $1,271.58 09/26/2025 Covered Recipient Physician Morpheus Melanoma No dispute reported 06/30/2026 1211538094
Principal investigator 1 PFIZER INC. $41,837.90 09/26/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SEACD70 IN MYELOID MALIGNANCIES No dispute reported 06/30/2026 1228824119
Principal investigator 1 PFIZER INC. $25,516.40 09/26/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228824125
Principal investigator 1 PFIZER INC. $11,313.60 09/26/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228824130
Principal investigator 1 Ipsen Pharma SAS $8,412.10 09/25/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303857
Principal investigator 1 Ipsen Pharma SAS $5,458.07 09/24/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303441
Principal investigator 1 Ipsen Pharma SAS $25,069.83 09/24/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303443
Principal investigator 1 PFIZER INC. $102,018.78 09/24/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228837528
Principal investigator 1 Ipsen Pharma SAS $2,341.08 09/19/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303447
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $430.30 09/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184241132
Principal investigator 1 Iovance Biotherapeutics, Inc. $59,934.40 09/18/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498365
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,875.00 09/18/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498367
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,388.00 09/18/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252498369
Principal investigator 1 Organon Llc $1,800.25 09/18/2025 Non-covered Recipient Entity
Cedars Sinai Medical Care Foundation
3475-587 No dispute reported 06/30/2026 1173042572
Principal investigator 1 Ipsen Pharma SAS $357.50 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303847
Principal investigator 1 Ipsen Pharma SAS $2,600.00 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303849
Principal investigator 1 Ipsen Pharma SAS $330.20 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303851
Principal investigator 1 Ipsen Pharma SAS $2,724.80 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303853
Principal investigator 1 Ipsen Pharma SAS $288.60 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303855
Principal investigator 1 Ipsen Pharma SAS $460.00 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303859
Principal investigator 1 Ipsen Pharma SAS $1,316.90 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303861
Principal investigator 1 Ipsen Pharma SAS $928.20 09/17/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,814.67 09/17/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184239780
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,906.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497731
Principal investigator 1 Iovance Biotherapeutics, Inc. $936.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497733
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,720.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497735
Principal investigator 1 Iovance Biotherapeutics, Inc. $5,265.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497737
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,875.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497739
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,430.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497741
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,240.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497743
Principal investigator 1 Iovance Biotherapeutics, Inc. $13,000.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497745
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,950.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497747
Principal investigator 1 Iovance Biotherapeutics, Inc. $343.20 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497749
Principal investigator 1 Iovance Biotherapeutics, Inc. $195.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497751
Principal investigator 1 Iovance Biotherapeutics, Inc. $338.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497753
Principal investigator 1 Iovance Biotherapeutics, Inc. $975.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497755
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,300.00 09/10/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497757
Recipient Regeneron Pharmaceuticals, Inc. $258.14 09/10/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118179
Principal investigator 1 Incyte Corporation $2,798.22 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601349
Principal investigator 1 Incyte Corporation $79,636.51 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601352
Principal investigator 1 Incyte Corporation $388.43 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601355
Principal investigator 1 Incyte Corporation $388.43 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601358
Principal investigator 1 Incyte Corporation $47.47 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601389
Principal investigator 1 Incyte Corporation $4,388.79 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601395
Principal investigator 1 Incyte Corporation $4,876.43 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601398
Principal investigator 1 Incyte Corporation $4,876.43 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601402
Principal investigator 1 Incyte Corporation $388.43 09/08/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601405
Principal investigator 1 Ipsen Pharma SAS $195.09 09/05/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303445
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,752.12 09/04/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051659
Recipient Regeneron Pharmaceuticals, Inc. $104.73 08/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118177
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $14,116.71 08/21/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051655
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $472.50 08/21/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051657
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,772.06 08/07/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051653
Principal investigator 1 Incyte Corporation $650.00 08/06/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601378
Principal investigator 1 Incyte Corporation $1,300.00 08/06/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601385
Principal investigator 1 Incyte Corporation $1,755.00 08/06/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601392
Principal investigator 1 PFIZER INC. $51,596.69 08/05/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228841301
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,370.00 07/31/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497955
Principal investigator 1 Iovance Biotherapeutics, Inc. $2,371.00 07/31/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497957
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,872.00 07/31/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497959
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,790.43 07/31/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051651
Principal investigator 1 Ipsen Pharma SAS $68.00 07/30/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303431
Principal investigator 1 Ipsen Pharma SAS $183.27 07/30/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303433
Principal investigator 1 Ipsen Pharma SAS $147.00 07/30/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303435
Principal investigator 1 Iovance Biotherapeutics, Inc. $596.00 07/25/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497729
Principal investigator 1 PFIZER INC. $42,684.20 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845758
Principal investigator 1 PFIZER INC. $19,763.90 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845829
Principal investigator 1 PFIZER INC. $17,171.70 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845838
Principal investigator 1 PFIZER INC. $9,152.00 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845846
Principal investigator 1 PFIZER INC. $416.00 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845854
Principal investigator 1 PFIZER INC. $7,894.90 07/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228845902
Principal investigator 1 Incyte Corporation $312.00 07/23/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601366
Principal investigator 1 Incyte Corporation $624.00 07/23/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601381
Principal investigator 1 Ipsen Pharma SAS $2,724.80 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303821
Principal investigator 1 Ipsen Pharma SAS $357.50 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303823
Principal investigator 1 Ipsen Pharma SAS $598.00 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303825
Principal investigator 1 Ipsen Pharma SAS $330.20 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303827
Principal investigator 1 Ipsen Pharma SAS $330.20 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303829
Principal investigator 1 Ipsen Pharma SAS $288.60 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303831
Principal investigator 1 Ipsen Pharma SAS $288.60 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303833
Principal investigator 1 Ipsen Pharma SAS $928.20 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303835
Principal investigator 1 Ipsen Pharma SAS $2,724.80 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303837
Principal investigator 1 Ipsen Pharma SAS $3,380.00 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303839
Principal investigator 1 Ipsen Pharma SAS $1,316.90 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303841
Principal investigator 1 Ipsen Pharma SAS $180.70 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303843
Principal investigator 1 Ipsen Pharma SAS $153.40 07/23/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303845
Principal investigator 1 PFIZER INC. $34,725.00 07/22/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228847377
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,256.22 07/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184216958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,943.60 07/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184214836
Principal investigator 1 Ipsen Pharma SAS $1,364.52 07/09/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303429
Principal investigator 1 Incyte Corporation $2,600.00 07/02/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601362
Principal investigator 1 Incyte Corporation $4,550.00 07/02/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601369
Principal investigator 1 Incyte Corporation $1,092.00 07/02/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $130.00 07/01/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184212361
Principal investigator 1 PFIZER INC. $3,000.00 06/26/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228852365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,839.60 06/25/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184210972
Principal investigator 1 Incyte Corporation $14,251.00 06/23/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601197
Principal investigator 1 Incyte Corporation $2,808.00 06/23/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $753.00 06/23/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184210254
Principal investigator 1 Merck Sharp & Dohme LLC $66,240.00 06/20/2025 Non-covered Recipient Entity
Cedars Sinai Medical Care Foundation
A phase 1b,2, multicenter, open-label study of S-531011 as monotherapy and in combination with an immune checkpoint inhibitor in participants with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1232935851
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,999.53 06/20/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184209882
Principal investigator 1 Ipsen Pharma SAS $4,093.55 06/19/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303427
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,375.00 06/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051643
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,725.00 06/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051645
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,500.00 06/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051647
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15,980.00 06/19/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1244051649
Principal investigator 1 Ipsen Pharma SAS $1,887.18 06/18/2025 Non-covered Recipient Entity
Exceptional Care Medical Group
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184306833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $331.50 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $351.00 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206877
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $403.00 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184207001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $557.70 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184207119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,392.00 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184207311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,661.10 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184207333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,542.50 06/16/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184207431
Principal investigator 1 Iovance Biotherapeutics, Inc. $375.00 06/13/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497033
Recipient Regeneron Pharmaceuticals, Inc. $119.77 06/06/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118175
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,077.74 06/05/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497027
Principal investigator 1 GlaxoSmithKline, LLC. $421.00 06/02/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166514
Principal investigator 1 Ipsen Pharma SAS $2,145.94 05/29/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184303425
Principal investigator 1 PFIZER INC. $31,725.00 05/23/2025 Non-covered Recipient Entity
CedarsSinai Medical Care Foundation
AN OPENLABEL PHASE 1 STUDY TO INVESTIGATE PF08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228855642
Principal investigator 1 Iovance Biotherapeutics, Inc. $6,250.00 05/22/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497029
Principal investigator 1 Iovance Biotherapeutics, Inc. $375.00 05/22/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497031
Principal investigator 1 Incyte Corporation $975.00 05/21/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601114
Principal investigator 1 Incyte Corporation $2,090.00 05/21/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601204
Principal investigator 1 Ipsen Pharma SAS $181.00 05/13/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184303423
Principal investigator 1 Iovance Biotherapeutics, Inc. $23,039.50 05/08/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497035
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,461.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497409
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,080.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497411
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,461.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497413
Principal investigator 1 Iovance Biotherapeutics, Inc. $489.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497471
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,550.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497475
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,950.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497477
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,092.00 05/07/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497479
Principal investigator 1 Ipsen Pharma SAS $2,361.68 05/05/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184303819
Recipient Regeneron Pharmaceuticals, Inc. $292.81 04/29/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118173
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 04/28/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166879
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 04/28/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166887
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 04/28/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170081
Principal investigator 1 GlaxoSmithKline, LLC. $354.00 04/28/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170090
Principal investigator 1 Ipsen Pharma SAS $3,057.18 04/25/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303813
Principal investigator 1 Ipsen Pharma SAS $3,792.57 04/25/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303815
Principal investigator 1 Ipsen Pharma SAS $2,890.78 04/25/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303817
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,500.00 04/23/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184189193
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,276.00 04/23/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184189195
Principal investigator 1 Immunocore Limited $765.35 04/17/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigators Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma No dispute reported 06/30/2026 1212145703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.64 04/11/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184183166
Principal investigator 1 Incyte Corporation $405.55 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601118
Principal investigator 1 Incyte Corporation $673.25 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601122
Principal investigator 1 Incyte Corporation $673.25 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601125
Principal investigator 1 Incyte Corporation $1,127.71 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601130
Principal investigator 1 Incyte Corporation $97.35 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601133
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601137
Principal investigator 1 Incyte Corporation $295.56 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601143
Principal investigator 1 Incyte Corporation $607.56 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601147
Principal investigator 1 Incyte Corporation $1,127.71 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601151
Principal investigator 1 Incyte Corporation $427.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601155
Principal investigator 1 Incyte Corporation $49.23 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601160
Principal investigator 1 Incyte Corporation $2,168.34 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601164
Principal investigator 1 Incyte Corporation $19.45 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601167
Principal investigator 1 Incyte Corporation $815.71 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601172
Principal investigator 1 Incyte Corporation $374.25 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601177
Principal investigator 1 Incyte Corporation $1,127.71 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601181
Principal investigator 1 Incyte Corporation $427.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601185
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601188
Principal investigator 1 Incyte Corporation $1,127.71 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601192
Principal investigator 1 Incyte Corporation $427.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601208
Principal investigator 1 Incyte Corporation $2,533.43 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601211
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601215
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601219
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601223
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601228
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601232
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601236
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601238
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601242
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601246
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601249
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601254
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601258
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601261
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601264
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601267
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601272
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601276
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601282
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601286
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601290
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601294
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601298
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601301
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601305
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601308
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601312
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601316
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601320
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601324
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601328
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601331
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601337
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601341
Principal investigator 1 Incyte Corporation $492.28 04/09/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601345
Principal investigator 1 Iovance Biotherapeutics, Inc. $3,989.00 04/09/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497469
Principal investigator 1 Iovance Biotherapeutics, Inc. $750.00 04/09/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497473
Principal investigator 1 PFIZER INC. $32,050.54 04/07/2025 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 1 STUDY OF SGNBB228 IN ADVANCED MELANOMA AND OTHER SOLID TUMORS No dispute reported 06/30/2026 1228778871
Recipient Regeneron Pharmaceuticals, Inc. $396.99 04/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118171
Recipient Regeneron Pharmaceuticals, Inc. $491.22 04/03/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,895.60 04/02/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184181118
Principal investigator 1 Incyte Corporation $18,713.10 03/28/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601082
Principal investigator 1 Iovance Biotherapeutics, Inc. $1,077.74 03/27/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497019
Principal investigator 1 Ipsen Pharma SAS $124.44 03/27/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303413
Principal investigator 1 Ipsen Pharma SAS $68.00 03/26/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303415
Principal investigator 1 Ipsen Pharma SAS $147.00 03/26/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303417
Principal investigator 1 Ipsen Pharma SAS $202.82 03/26/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303419
Principal investigator 1 Ipsen Pharma SAS $1,086.00 03/06/2025 Non-covered Recipient Entity
Cedars Sinai The Angeles Clinic And Research Institute
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303421
Principal investigator 1 Incyte Corporation $2,600.00 03/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601057
Principal investigator 1 Incyte Corporation $357.14 03/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601078
Principal investigator 1 Incyte Corporation $1,092.00 03/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601085
Principal investigator 1 Incyte Corporation $975.00 03/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601092
Principal investigator 1 Incyte Corporation $43,627.90 03/03/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601106
Principal investigator 1 Incyte Corporation $1,300.00 03/03/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 1240601109
Principal investigator 1 Iovance Biotherapeutics, Inc. $12,000.00 02/27/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,736.10 02/27/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184155970
Recipient Regeneron Pharmaceuticals, Inc. $148.22 02/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118167
Principal investigator 1 GlaxoSmithKline, LLC. $366.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166518
Principal investigator 1 GlaxoSmithKline, LLC. $1,626.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166523
Principal investigator 1 GlaxoSmithKline, LLC. $345.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166527
Principal investigator 1 GlaxoSmithKline, LLC. $585.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166530
Principal investigator 1 GlaxoSmithKline, LLC. $5,603.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166861
Principal investigator 1 GlaxoSmithKline, LLC. $3,550.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166865
Principal investigator 1 GlaxoSmithKline, LLC. $95.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166869
Principal investigator 1 GlaxoSmithKline, LLC. $3,763.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166874
Principal investigator 1 GlaxoSmithKline, LLC. $585.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166883
Principal investigator 1 GlaxoSmithKline, LLC. $585.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192166891
Principal investigator 1 GlaxoSmithKline, LLC. $1,040.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170086
Principal investigator 1 GlaxoSmithKline, LLC. $585.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170095
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170099
Principal investigator 1 GlaxoSmithKline, LLC. $3,137.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170103
Principal investigator 1 GlaxoSmithKline, LLC. $2,955.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170107
Principal investigator 1 GlaxoSmithKline, LLC. $519.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170111
Principal investigator 1 GlaxoSmithKline, LLC. $1,038.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170114
Principal investigator 1 GlaxoSmithKline, LLC. $1,690.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170484
Principal investigator 1 GlaxoSmithKline, LLC. $90.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170488
Principal investigator 1 GlaxoSmithKline, LLC. $1,830.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170492
Principal investigator 1 GlaxoSmithKline, LLC. $4,550.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170500
Principal investigator 1 GlaxoSmithKline, LLC. $585.00 02/24/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE
A PHASE 1 FIRST-TIME-IN-HUMAN, OPEN-LABEL STUDY OF GSK6097608 ADMINIST No dispute reported 06/30/2026 1192170504
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,527.00 02/21/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1 STUDY OF REGN6569, AN ANTI-GITR MAB, WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCIES No dispute reported 06/30/2026 1184155344
Principal investigator 1 Iovance Biotherapeutics, Inc. $7,500.00 02/20/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497017
Principal investigator 1 Iovance Biotherapeutics, Inc. $21,625.00 02/20/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497021
Principal investigator 1 Iovance Biotherapeutics, Inc. $4,250.00 02/20/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
NCT02360579 No dispute reported 06/30/2026 1252497023
Principal investigator 1 Celgene Corporation $15,866.00 02/14/2025 Non-covered Recipient Entity
Cedars Sinai Medical Care Foundation Pharmacy
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors No dispute reported 06/30/2026 1222305722
Principal investigator 1 Celgene Corporation $15,184.00 02/14/2025 Non-covered Recipient Entity
Cedars Sinai Medical Care Foundation Pharmacy
A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors No dispute reported 06/30/2026 1222305784
Recipient Regeneron Pharmaceuticals, Inc. $238.92 02/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118163
Recipient Regeneron Pharmaceuticals, Inc. $230.40 02/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184118165
Principal investigator 1 Incyte Corporation $1,092.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601062
Principal investigator 1 Incyte Corporation $650.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601066
Principal investigator 1 Incyte Corporation $4,550.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601070
Principal investigator 1 Incyte Corporation $1,755.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601074
Principal investigator 1 Incyte Corporation $750.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601095
Principal investigator 1 Incyte Corporation $2,600.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601099
Principal investigator 1 Incyte Corporation $1,300.00 02/05/2025 Non-covered Recipient Entity
THE ANGELES CLINIC AND RESEARCH INSTITUTE
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors No dispute reported 06/30/2026 1240601102
Principal investigator 1 Iovance Biotherapeutics, Inc. $588.00 01/27/2025 Non-covered Recipient Entity
Cedars-Sinai Medical Center
NCT05361174 No dispute reported 06/30/2026 1252497349
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $30,491.00 01/17/2025 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab andNivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma [RELAtivity-098] No dispute reported 06/30/2026 1236001643
Principal investigator 1 Novartis Pharmaceuticals Corporation $47,600.77 01/14/2025 Non-covered Recipient Entity
CEDARSSINAI MEDICAL CARE FOUNDATION
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma No dispute reported 06/30/2026 1190309166
Principal investigator 1 Ipsen Pharma SAS $3,250.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303801
Principal investigator 1 Ipsen Pharma SAS $1,300.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303803
Principal investigator 1 Ipsen Pharma SAS $3,640.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303805
Principal investigator 1 Ipsen Pharma SAS $3,000.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303807
Principal investigator 1 Ipsen Pharma SAS $4,550.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303809
Principal investigator 1 Ipsen Pharma SAS $13,000.00 01/10/2025 Non-covered Recipient Entity
Cedars Sinai Internal Medicine Encino
An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours No dispute reported 06/30/2026 1184303811
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $103,786.28 01/09/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184147331
Principal investigator 1 Eli Lilly and Company $4,554.00 01/03/2025 Non-covered Recipient Entity
CEDARS SINAI MEDICAL CARE FOUNDATION
Not supplied No dispute reported 06/30/2026 1187883368